<DOC>
	<DOCNO>NCT00041249</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness brostallicin treat patient locally advance metastatic soft tissue sarcoma respond one previous chemotherapy regimen .</brief_summary>
	<brief_title>Brostallicin Treating Patients With Locally Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity brostallicin , term objective response , patient locally advance metastatic soft tissue sarcoma fail one prior chemotherapy treatment . - Determine time progression duration response patient treated drug . - Determine safety toxic effect drug patient . - Correlate clinical outcome whole blood glutathione level patient treat drug . OUTLINE : This multicenter study . Patients stratify accord tumor ( tumor gastrointestinal stromal tumor ( GIST ) v GIST ) . Patients receive brostallicin IV 10 minute day 1 . Treatment repeat every 21 day least 4 course absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year every 4 month 1 year . PROJECTED ACCRUAL : A total 58-72 patient ( 40 stratum I 18-32 stratum II ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma amenable surgery , radiotherapy , combine modality therapy curative intent Stratum I Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma include hemangiopericytoma Malignant peripheral nerve sheath tumor Unclassified sarcoma Miscellaneous sarcoma Stratum II Gastrointestinal stromal tumor Previously treat imatinib mesylate locally advance metastatic disease demonstrate disease progression The following sarcoma type exclude : Mixed mesodermal tumor uterus ( carcinosarcoma ) Chondrosarcoma Malignant mesothelioma Neuroblastoma Osteosarcoma Ewing 's sarcoma Embryonal rhabdomyosarcoma At least one measurable lesion Progressive disease 1 prior anthracycline and/or alkylatingcontaining chemotherapy regimen locally advance metastatic disease Clinical evidence progression within 6 week prior study treatment No known symptomatic CNS metastases PATIENT CHARACTERISTICS : Age : Over 15 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGPT SGOT great 3 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance great 65 mL/min Cardiovascular : No prior severe cardiovascular disease Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 6 month study No prior concurrent malignancy except adequately treat basal cell skin cancer carcinoma situ cervix No severe medical illness No psychosis PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic response modifier immunotherapy No concurrent prophylactic hematopoietic growth factor ( e.g. , filgrastim ( G CSF ) sargramostim ( GMCSF ) Chemotherapy : See Disease Characteristics More 4 week since prior chemotherapy recover Prior adjuvant chemotherapy firstline treatment allow provided disease progress within 6 month completion chemotherapy No prior ecteinascidin 743 ( stratum I ) No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Recovered prior radiotherapy No prior radiotherapy sole measurable lesion Concurrent palliative radiotherapy nontarget lesion allow investigator 's discretion Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent anticancer therapy ( approved investigational ) No concurrent participation clinical treatment study No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>